The major safety concerns that lead to the termination of clinical drug development programs and the withdrawal of approved drugs from the market are related to the cardiovascular system and the liver. The most frequent cardiovascular adverse event that prompts drug withdrawals is the potentially life-threatening cardiac arrhythmia known as Torsades de Pointes (TdP). Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, has shown promise in treating various tumors but raises concerns regarding its cardiovascular safety. This study aims to comprehensively evaluate the proarrhythmic risks associated with Sunitinib, employing an integrated platform that spans both in vitro and ex vivo analyses.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
